此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Phase 1, First-in-Human Study of CITY-RBP4 in Healthy Volunteers and STGD1 Participants

2026年9月22日 更新者:City Therapeutics

A Phase 1, Randomized, Double-Masked, Placebo-Controlled, Single-Ascending and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CITY-RBP4 Administered Subcutaneously in Healthy Volunteers and Participants With Stargardt Disease Type 1 (STGD1)

This is a first-in-human (FIH), multicenter, randomized, double-masked, placebo-controlled adaptive clinical study evaluating the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of CITY-RBP4, following single-ascending doses and multiple doses, via subcutaneous (SC) administration.

研究概览

详细说明

The study consists of 3 sequential parts:

  • Part A: Single-ascending doses in healthy volunteers
  • Part B: Single-ascending doses in participants with Stargardt Disease Type 1 (STGD1)
  • Part C: Multiple doses in participants with Stargardt Disease Type 1 (STGD1)

研究类型

介入性

注册 (估计的)

48

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

12年 至 45年 (孩子、成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Key Inclusion Criteria (Part A):

  1. Willing and able to provide written informed consent form
  2. Be aged 18 to 45 years (inclusive) at the time of signing the informed consent form
  3. Generally healthy on medical history, exam, labs, and ECG
  4. BCVA 20/25 or better in each eye
  5. Serum retinol above protocol threshold
  6. Body weight ≥40 kg and BMI of 18.0 to 32.0 kg/m2
  7. Men and WOCBP must agree to use highly effective methods of contraception or practice abstinence from 30 days before the first dose of CITY-RBP4, throughout the study, and for at least 180 days after treatment with CITY-RBP4 or the last study visit, whichever is longer; men must refrain from donating or banking sperm during the same period
  8. Female participants who are not WOCBP should meet at least 1 of the following criteria: have undergone a documented hysterectomy, bilateral oophorectomy, and/or bilateral salpingectomy; have medically confirmed ovarian failure, or achieved postmenopausal status

Key Exclusion Criteria (Part A):

  1. Clinically significant ocular disease or prior ocular surgery that could interfere with safety assessments
  2. History of vitamin A deficiency, malabsorption, or chronic diarrhea
  3. Clinically significant cardiac, hepatic, renal, pulmonary, neurologic, or psychiatric disease
  4. Positive hepatitis B, hepatitis C, or HIV screening
  5. Prior RNAi/oligonucleotide therapy or recent investigational treatment
  6. Recent vitamin A-related supplements, retinoids, or medications affecting vitamin A metabolism
  7. Pregnancy or breastfeeding, if applicable

Key Inclusion Criteria (Parts B and C)

  1. Participants aged 12 to 45 years
  2. Clinical diagnosis of STGD1 with documented ABCA4 pathogenic/likely pathogenic variant
  3. Minimum BCVA is required in the study eye
  4. Subjects must have a defined aggregate atrophic lesion in 1 or both eyes
  5. Body weight ≥40 kg
  6. Able to complete key ophthalmic safety assessments and comply with study precautions

Key Exclusion Criteria (Parts B and C)

  1. Ocular conditions that could confound retinal imaging or safety evaluation
  2. Prior ocular gene therapy, stem cell therapy, or retinal implant
  3. Vitamin A deficiency or recent prohibited vitamin A-related treatments
  4. Recent interventional study participation
  5. Clinically significant non-ophthalmic disease, abnormal screening labs/ECG, or positive hepatitis B, hepatitis C, or HIV screening
  6. Pregnancy or breastfeeding, if applicable

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:顺序分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:在健康成人中(A部分)

Saline (subcutaneous injection)

实验性的:CITY-RBP4 in Healthy Adults (Part A)

siRNA (subcutaneous injection)

实验性的:CITY-RBP4 in Participants with STGD1 (Parts B & C)

siRNA (subcutaneous injection)

安慰剂比较:In Participants with STGD1 (Parts B & C)

Saline (subcutaneous injection)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence, severity, and relationship of treatment-emergent adverse events (TEAEs)
大体时间:Through study completion, up to Day 360

To evaluate the safety and tolerability of single and multiple doses of CITY-RBP4 in healthy adults and participants with Stargardt disease Type 1 (STGD1)

Through study completion, up to Day 360

次要结果测量

结果测量
措施说明
大体时间
Plasma concentrations of CITY-RBP4
大体时间:Day 1 to Day 2

To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1

Day 1 to Day 2
Urine concentrations of CITY-RBP4
大体时间:Part A and B only: Day 1 to Day 2

To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after a single dose of CITY-RBP4 in healthy adults and participants with STGD1

Part A and B only: Day 1 to Day 2
Maximum plasma concentration (Cmax)
大体时间:Day 1 to Day 2

To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1

Day 1 to Day 2
Time to maximum plasma concentration (Tmax)
大体时间:Day 1 to Day 2

To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1

Day 1 to Day 2
Area under plasma concentration-time curve (AUC)
大体时间:Day 1 to Day 2

To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1

Day 1 to Day 2
Terminal elimination half-life (t1/2)
大体时间:Day 1 to Day 2

To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1

Day 1 to Day 2
Apparent clearance (CL/F)
大体时间:Day 1 to Day 2

To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1

Day 1 to Day 2
Amount excreted unchanged (Ae)
大体时间:Part A and B only: Day 1 to Day 2

To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after a single dose of CITY-RBP4 in healthy adults and participants with STGD1

Part A and B only: Day 1 to Day 2
Change from baseline in plasma RBP4 concentrations
大体时间:Up to Day 360

evaluate the pharmacodynamic (PD) effects of CITY-RBP4 on plasma retinol-binding protein 4 (RBP4) levels after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1

Up to Day 360
Change from baseline in serum retinol concentrations
大体时间:Up to Day 360

To evaluate the pharmacodynamic (PD) effects of CITY-RBP4 on serum retinol levels after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1

Up to Day 360

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Medical Director、City Therapeutics

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年9月1日

初级完成 (估计的)

2028年2月1日

研究完成 (估计的)

2028年4月1日

研究注册日期

首次提交

2026年9月16日

首先提交符合 QC 标准的

2026年9月22日

首次发布 (实际的)

2026年9月23日

研究记录更新

最后更新发布 (实际的)

2026年9月23日

上次提交的符合 QC 标准的更新

2026年9月22日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅